HIV treatment has been improved and simplified significantly over the years yet a small fraction of people living with HIV still take complex multi-pill regimens. Elri Voigt reports on a new combination pill that could make life easier for some in this group. But as two leading experts point out, the development comes against a backdrop where the traditional categorisation of HIV medicines is dissolving.
Just over a month after US President Donald Trump implemented a 90-day freeze of all foreign assistance, the future looks very uncertain for tuberculosis research. Among others, a large TB research programme that was worth up to $200 million was axed last week. Elri Voigt reports.
South African scientists have echoed serious concerns flagged in a recent UN Environmental Programme Report on the growth of antimicrobial resistance in the environment. Sue Segar reports.
A study published last year on an HIV variant that has been circulating in the Netherlands for the last 20 years reminded the public of the existence of viral variants beyond SARS-CoV-2. Elri Voigt unpacks what we know about the HI-virus, its variants, and the study’s findings.
Antibiotics play a vital role in the management of bacterial infections, reducing illness, and preventing many deaths. Tiyese Jeranji looks at how antimicrobial resistance plays out in South Africa and the role of pharmacists in the fight against it.
Tuberculosis (TB) can be resistant to treatment with several different drugs. Tests that identify which drugs someone’s TB is resistant to are critical to ensuring that people are not treated with drugs that don’t work for them, especially given the significant side effects associated with some of the drugs. Elri Voigt assesses the state of play in testing for TB drug resistance and the promise of exciting new technologies, such as whole genome sequencing.
Despite the global emergence of highly resistant strains of gonorrhoea, including untreatable variants, a new antibiotic for the disease has not been developed in over half a century. In January, a trial began in South Africa and other countries for a new gonorrhoea antibiotic. But what is gonorrhoea? How significant is the problem in South Africa and among those living with HIV? Do we have resistant strains too? Experts report a grim situation, but with hope on the horizon. Amy Green reports.
A leading TB doctor says that “it is no exaggeration to say there is a TB crisis in the country”, and that “the impact of this crisis could be even more devastating than COVID-19”. Kathryn Cleary explores the COVID-19 pandemic’s impact on South Africa’s TB response and the way forward.
Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.
